Abstract
The Serratia marcescens hemolysin represents a new type of hemolysin and has been studied in great molecular detail with regard to structure, activation and secretion. It has nothing in common with the pore forming toxins of E. coli type (RTX toxins), the Staphylococcus aureus α-toxin or the thiol activated toxin of group A β-hemolytic streptococci (Streptolysin O). Studies on erythrocytes, eukaryotic cells and artificial black lipid membranes, have shown that the mechanism of pore formation of ShlA is different form other pore forming toxins. The S. marcescens hemolysin proteins ShlB and ShlA exhibit protein sequence homologues in Proteus mirabilis, Haemophilus ducreyi, Edwardsiella tarda and Erwinia chrysantemi. Furthermore, sequence motifs present in ShlA and Shlb have been shown to be important for activity and secretion of the S. marcescens hemolysin. Thus, the S. marcescens hemolysin forms the prototype of a new class of hemolysins and of a new secretory mechanism. The uniqueness of this new mechanism is underlined by the fact that activation of ShlA by ShlB strictly requires phosphatidylethanolamine as a cofactor. New data implicate a conformational change in ShlA during activation. In addition, ShlA not only forms pores in erythrocytes but also in fibroblasts and epithelial cells. The cytotoxic action of ShlA is mainly determined by lysis of infected cells in vitro. In sublytic doses, as will normally be the situation in vivo, ShlA exerts additionally effects which are currently under investigation. The knowledge of the structure, activation, secretion and mode of action of S. marcescens hemolysin has implications for proteins, related in sequence or in mode of secretion and activation.
Current Protein & Peptide Science
Title: Serratia Type Pore Forming Toxins
Volume: 1 Issue: 1
Author(s): Ralf Hertle
Affiliation:
Abstract: The Serratia marcescens hemolysin represents a new type of hemolysin and has been studied in great molecular detail with regard to structure, activation and secretion. It has nothing in common with the pore forming toxins of E. coli type (RTX toxins), the Staphylococcus aureus α-toxin or the thiol activated toxin of group A β-hemolytic streptococci (Streptolysin O). Studies on erythrocytes, eukaryotic cells and artificial black lipid membranes, have shown that the mechanism of pore formation of ShlA is different form other pore forming toxins. The S. marcescens hemolysin proteins ShlB and ShlA exhibit protein sequence homologues in Proteus mirabilis, Haemophilus ducreyi, Edwardsiella tarda and Erwinia chrysantemi. Furthermore, sequence motifs present in ShlA and Shlb have been shown to be important for activity and secretion of the S. marcescens hemolysin. Thus, the S. marcescens hemolysin forms the prototype of a new class of hemolysins and of a new secretory mechanism. The uniqueness of this new mechanism is underlined by the fact that activation of ShlA by ShlB strictly requires phosphatidylethanolamine as a cofactor. New data implicate a conformational change in ShlA during activation. In addition, ShlA not only forms pores in erythrocytes but also in fibroblasts and epithelial cells. The cytotoxic action of ShlA is mainly determined by lysis of infected cells in vitro. In sublytic doses, as will normally be the situation in vivo, ShlA exerts additionally effects which are currently under investigation. The knowledge of the structure, activation, secretion and mode of action of S. marcescens hemolysin has implications for proteins, related in sequence or in mode of secretion and activation.
Export Options
About this article
Cite this article as:
Hertle Ralf, Serratia Type Pore Forming Toxins, Current Protein & Peptide Science 2000; 1 (1) . https://dx.doi.org/10.2174/1389203003381423
DOI https://dx.doi.org/10.2174/1389203003381423 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
Call for Papers in Thematic Issues
Advancements in Proteomic and Peptidomic Approaches in Cancer Immunotherapy: Unveiling the Immune Microenvironment
The scope of this thematic issue centers on the integration of proteomic and peptidomic technologies into the field of cancer immunotherapy, with a particular emphasis on exploring the tumor immune microenvironment. This issue aims to gather contributions that illustrate the application of these advanced methodologies in unveiling the complex interplay ...read more
Artificial Intelligence for Protein Research
Protein research, essential for understanding biological processes and creating therapeutics, faces challenges due to the intricate nature of protein structures and functions. Traditional methods are limited in exploring the vast protein sequence space efficiently. Artificial intelligence (AI) and machine learning (ML) offer promising solutions by improving predictions and speeding up ...read more
Nutrition and Metabolism in Musculoskeletal Diseases
The musculoskeletal system consists mainly of cartilage, bone, muscles, tendons, connective tissue and ligaments. Balanced metabolism is of vital importance for the homeostasis of the musculoskeletal system. A series of musculoskeletal diseases (for example, sarcopenia, osteoporosis) are resulted from the dysregulated metabolism of the musculoskeletal system. Furthermore, metabolic diseases (such ...read more
Protein/protein and RNA/protein interactions are essential for molecular regulations
Protein-protein and RNA-protein interactions are fundamental to the intricate regulatory mechanisms that govern various cellular processes, playing a crucial role in maintaining the delicate balance and coordination within the complex molecular landscape. Proteins, the workhorses of the cell, engage in a myriad of interactions, both with other proteins and with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiac Workup of Ischemic Stroke
Current Cardiology Reviews Recent Advances in Natural Product-Based Anti-Biofilm Approaches to Control Infections
Mini-Reviews in Medicinal Chemistry Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor
Current Pharmaceutical Design Acute Decompensated Heart Failure Update
Current Cardiology Reviews Lantibiotic Production by Pathogenic Microorganisms
Current Protein & Peptide Science Production and Application of Bacteriophage and Bacteriophage-Encoded Lysins
Recent Patents on Biotechnology Endophthalmitis
Anti-Infective Agents in Medicinal Chemistry Secondary Prevention of Ischemic Stroke
Current Drug Targets Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design Platelets as Potential Immunomodulators: Is There a Role for Platelet Toll-Like Receptors?
Current Immunology Reviews (Discontinued) Protective Effects of Astaxanthin on Nephrotoxicity in Rats with Induced Renovascular Occlusion
Combinatorial Chemistry & High Throughput Screening Antibacterial Efficacy of Abrus precatorius L. and Asystasia gangetica (L.) T. Anderson
Anti-Infective Agents 'Mucormycosis': A Fungal Infection Threatening India During COVID-19' - A Review
Anti-Infective Agents Noncardiac Surgery: Evaluating and Minimizing Cardiac Risk
Current Cardiology Reviews The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Systemic Fungal Infections Caused by Candida Species: Epidemiology, Infection Process and Virulence Attributes
Current Drug Targets The Development of Antimicrobial Peptides as New Antibacterial Drugs
Current Protein & Peptide Science Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Kawasaki Disease and Its Treatment – An Update
Current Rheumatology Reviews COVID-19 and the Challenges of Chemotherapy: The Failure Case of Hydroxychloroquine in the Clinical Treatment of SARS-CoV-2 Infection
Coronaviruses